Future prospective studies should include KRAS/SMARCA4 class 1 and KRAS/SMARCA4 class 2 cohorts to validate the prognostic effects and potential predictive value of these co-mutations on survival outcomes in this high-risk NSCLC population. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.